A genome-wide association study of schizophrenia appearing in Nature Communications suggests that a variant in a chromosome 4 gene called NDST3 contributes to the risk of both schizophrenia and bipolar disorder. Researchers used Illumina Human Omni1-Quad arrays to genotype thousands of schizophrenia cases and controls from the Ashkenazi Jewish population. They found a handful of SNPs with apparent genome-wide significant ties to the condition, though the association was most pronounced for NDST3.
Illumina received premarket clearance from the US Food and Drug Administration for its MiSeqDx system, two cystic fibrosis assays, and a library prep kit that enables laboratories to develop their own diagnostic tests. The two cystic fibrosis assays include the MiSeqDx Cystic Fibrosis 139-Variant Assay, the MiSeqDx Cystic Fibrosis Clinical Sequencing Assay, and the MiSeqDx Universal Kit, which includes library preparation reagents, sample index primers, and sequencing consumables. This is the first time a next-gen sequencing system has received FDA clearance.
The UK's Medical Research Council plans to invest more than £150 million ($241 million) to beef up its national clinical research chops in key areas by funding the acquisition and development of new technologies. The funding call centers on supporting technologies for research in three fields: stratified and experimental medicine, single cell-level functional genomics, and dementia research. MRC also wants applicants to seek out or create partnerships with industry and existing clinical research infrastructures.
GenomeWeb and Asuragen invite you to view a webinar discussing the use of next-generation sequencing to illuminate druggable targets in oncology while addressing the limitations in DNA quality and yield from formalin-fixed specimens.
Register here to view the playback or download the recording.